Showing 2,021 - 2,040 results of 2,072 for search '(( significant decrease decrease ) OR ( significant progressive decrease ))~', query time: 0.36s Refine Results
  1. 2021

    Table 1_Hypothalamic FTO upregulates BDNF to promote GnRH expression through the PI3K/Akt pathway, leading to precocious puberty.docx by Shaolian Zang (11987905)

    Published 2025
    “…</p>Results<p>Hypothalamic GnRH and FTO expression progressively increased whereas m6A methylation decreased during puberty. …”
  2. 2022

    Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
  3. 2023

    Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). …”
  4. 2024

    Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
  5. 2025

    Image 3_Hypothalamic FTO upregulates BDNF to promote GnRH expression through the PI3K/Akt pathway, leading to precocious puberty.tif by Shaolian Zang (11987905)

    Published 2025
    “…</p>Results<p>Hypothalamic GnRH and FTO expression progressively increased whereas m6A methylation decreased during puberty. …”
  6. 2026

    Table 1_FBR2 modulates ferroptosis via the SIRT3/p53 pathway to ameliorate pulmonary fibrosis.docx by Yu Cheng (136592)

    Published 2025
    “…FBR2 decreased collagen deposition in lung tissue, as shown by Masson’s staining and IHC detection of Col-I and α-SMA, confirming its anti-fibrotic effects. …”
  7. 2027

    Table 1_Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice.xlsx by Rui Tang (298719)

    Published 2025
    “…Single-cell sequencing revealed that Resveratrol primarily targeted colonocytes, decreasing genes related to apoptosis and the P53 pathway. …”
  8. 2028

    Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
  9. 2029

    Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
  10. 2030

    Table 2_FBR2 modulates ferroptosis via the SIRT3/p53 pathway to ameliorate pulmonary fibrosis.xlsx by Yu Cheng (136592)

    Published 2025
    “…FBR2 decreased collagen deposition in lung tissue, as shown by Masson’s staining and IHC detection of Col-I and α-SMA, confirming its anti-fibrotic effects. …”
  11. 2031

    Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
  12. 2032

    Image 2_Hypothalamic FTO upregulates BDNF to promote GnRH expression through the PI3K/Akt pathway, leading to precocious puberty.tif by Shaolian Zang (11987905)

    Published 2025
    “…</p>Results<p>Hypothalamic GnRH and FTO expression progressively increased whereas m6A methylation decreased during puberty. …”
  13. 2033

    Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). …”
  14. 2034

    Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). …”
  15. 2035

    Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). …”
  16. 2036

    Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). …”
  17. 2037

    Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
  18. 2038

    Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
  19. 2039

    Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). …”
  20. 2040

    Image 1_Hypothalamic FTO upregulates BDNF to promote GnRH expression through the PI3K/Akt pathway, leading to precocious puberty.tif by Shaolian Zang (11987905)

    Published 2025
    “…</p>Results<p>Hypothalamic GnRH and FTO expression progressively increased whereas m6A methylation decreased during puberty. …”